Roche has received a positive recommendation from the EMA's CHMP for Ocrevus to treat pediatric patients with relapsing forms of multiple sclerosis. This expands the drug's market potential in Europe, building on its prior FDA approval for the same indication, and offers a new high-efficacy treatment option for a vulnerable patient population.
Roche's Ocrevus has received a positive opinion from the EMA's CHMP for pediatric relapsing multiple sclerosis, following its FDA approval in May 2026. This is a significant development as it opens up a new, underserved market segment for Ocrevus in Europe, where approximately one-third of the 40,000 pediatric MS patients worldwide reside. The positive opinion is based on strong Phase III data showing Ocrevus's non-inferiority to fingolimod (Novartis's Gilenya) in controlling relapses and superiority in reducing brain inflammation. This news is a short-term positive catalyst for Roche, indicating potential revenue growth from an expanded label. For Novartis, it represents increased competition in the pediatric MS market. The long-term implication is improved treatment options for pediatric MS patients and continued market dominance for Ocrevus in MS treatment.